Arno Therapeutics, Inc.
| OTC Markets: ARNI
Arno Therapeutics, Inc. operates as a development stage company, which focuses on developing innovative products for the treatment of cancer. The company has worldwide rights to develop and market three innovative clinical-stage anti-cancer product candidates with mechanisms of action. The compounds are in clinical testing as potential best- or first-in-class products to treat hematologic malignancies and solid tumors. Arno Therapeutics was founded by Peter Morgan Kash, Tanen M. David and Joshua A. Kazam in March 2000 and is headquartered in Flemington, NJ.